Surface Oncology, Inc. (SURF) |
|
1.07 -0.01 (-0.93%)
|
09-07 16:00 |
|
Open: |
1.06 |
Pre. Close: |
1.08 |
|
High:
|
1.09 |
Low:
|
1.01 |
|
Volume:
|
1,462,284 |
Market Cap:
|
65(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:22:22 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.3 One year: 1.52 |
| Support: |
Support1: 0.93 Support2: 0.82 |
| Resistance: |
Resistance1: 1.12 Resistance2: 1.3 |
| Pivot: |
1.03 |
| Moving Average: |
MA(5): 1.07 MA(20): 1
MA(100): 0.84 MA(250): 0.87 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 79.7 %D(3): 81.7 |
| RSI: |
RSI(14): 61.4 |
| 52-week: |
High: 1.42 Low: 0.55 |
| Average Vol(K): |
3-Month: 811 (K) 10-Days: 414 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SURF ] has closed below upper band by 31.0%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.07 - 1.08 |
1.08 - 1.08 |
|
Low:
|
1.06 - 1.06 |
1.06 - 1.07 |
|
Close:
|
1.06 - 1.07 |
1.07 - 1.08 |
|
Company Description |
|
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 20 Sep 2023
Efficacy of copper nanoparticles encapsulated in soya lecithin ... - Nature.com
Thu, 31 Aug 2023
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences - Yahoo Finance
Tue, 29 Aug 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ... - GlobeNewswire
Tue, 15 Aug 2023
Surface Oncology And Coherus BioSciences: Does A Buyout Equal ... - Seeking Alpha
Wed, 02 Aug 2023
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 - Yahoo Finance
Tue, 01 Aug 2023
Moore Kuehn Encourages PACW, NEWR, CFMS, and SURF ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
61 (M) |
| Shares Float |
49 (M) |
|
% Held by Insiders
|
7.2 (%) |
|
% Held by Institutions
|
46 (%) |
|
Shares Short
|
165 (K) |
|
Shares Short P.Month
|
285 (K) |
Stock Financials |
|
EPS
|
-1.56 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.81 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-41.5 |
|
Return on Equity (ttm)
|
-105.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.61 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.37 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-84 (M) |
|
Levered Free Cash Flow
|
-52 (M) |
Stock Valuations |
|
PE Ratio
|
-0.69 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.32 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.78 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
